MONTREAL, QUEBEC--(Marketwire - November 23, 2007) - Mistral Pharma Inc. (TSX VENTURE: MIP) (the "Corporation", "Mistral") announces today its financial results and review of operating highlights for the second quarter and for the six-month period ended September 30, 2007. "The highlights of Mistral's second quarter were the successful pilot clinical trial of our MIST-B03 product, the signing of a method use license for our MIST-B02 product and of course, the preparation for the launch of the recently approved Instillagel® by Health Canada ", said Bertrand Bolduc, the Corporation's President & CEO. "As planned, we had a successful product launch at the beginning of November 2007 "he added.
